14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide A/S publishes interim report for the period January – June 2022


August 25, 2022

Copenhagen, Denmark, 25 August 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 June 2022. The Q2 report is available as an attached document to this press release and on FluoGuide’s website. lFilings & reports – FluoGuide A/S (

In H1 2022, FluoGuide reached a major milestone in the clinical development showing that FG001 is very well tolerated and FG001 illuminates aggressive brain cancer. This has significantly de-risked FG001.

FluoGuide had no revenue for the period and therefore posted a net loss of KDKK -9,702 for the period 1 January to 30 June 2022 (-7,778).  The financial result for the period is in line with the Company's development plans.  It is the Board’s opinion that FluoGuide, unlike many other life science companies, may have a comparatively short time from the initiation of product development to revenue generation.

Summary Q2 22 Q2 21 H1 22 H1 21 2021
01-apr-22 01-apr-21 01-jan-22 01-jan-21 01-jan-21
(KDKK) 30-jun-22 30-jun-21 30-jun-22 30-jun-21 31-dec-21
Net Revenue 
Operating result -7.514 -6.034 -12.942 -10.233 -28.809
Net result  -5.749 -4.437 -9.702 -7.778 -23.770
Cash and bank  39.136 49.712 39.136 49.712 46.758
Result per share (DKK) *) -0,50 -0,40 -0,83 -0,72 -2,15
Solidity (%) **) 92% 82% 92% 82% 73%
Avarage shares for the period 11.435.000 10.963.803 11.625.798 10.748.113 11.036.155

a *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. .   

**) Solidity:  Total equity divided by total capital and liability.


  • FluoGuide announces positive top line result from the first part of the ongoing clinical phase I/II trial testing the safety and performance of FG001 in lightening up aggressive brain cancer
  • Presentation of clinical data on FG001 at the 68th Scandinavian Neurosurgical Society Congress held 14-16 May 2022 in Bergen, Norway 
  • FluoGuide published interim report for the period January – March 2022 on 31 May 2022


  • Investor presentations in second half of 2022
  • A publication of clinical data that shows uPAR is highly expressed Head and Neck cancer
  • Submitted CTA to initiate phase IIa in Head and Neck cancer
    Update on FluoGuide clinical programs

Morten Albrechtsen, CEO says: “FluoGuide reached a major milestone in its development in H1 2022, with the exciting data from our phase I/IIa trial of FG001 in aggressive brain cancer, as it makes it significantly more likely that FG001 will become a commercial product”